Accepted by the WHO and EORTC as a variant of classic mycosis fungoides, folliculotropic (syn.: follicular or pilotropic) mycosis fungoides (FMF) is characterized by a broad clinical and histological spectrum with numerous differential diagnoses. Recent studies have shown that FMF can be divided into two prognostically different subgroups, both marked by histological as well as clinical differences. Treatment should therefore be tailored to the various subtypes and clinical courses. The present review highlights the clinical and histological manifestations of FMF as well as the new subclassification. Moreover, important differential diagnoses and therapeutic options are discussed.
Introduction
Folliculotropic mycosis fungoides (FMF) is recognized by the WHO/EORTC (World Health Organization/European Organization of Research and Treatment of Cancer) as a variant of classic mycosis fungoides (MF) [ 1 ] . Given its broad clinical spectrum, the diagnosis of FMF is particularly challenging and frequently requires clinicopathologic correlation. Histological hallmark is a folliculotropic infi ltrate of atypical T lymphocytes, predominantly CD4-positive cells [ 1 ] . Until recently, it had been assumed that FMF was generally associated with an unfavorable prognosis [ 1 ] . However, recent studies have shown that FMF can be divided into two prognostically different subtypes [ 2, 3 ] . In the present review, we highlight the various clinical and histological manifestations of FMF and discuss therapeutic options as well as current prognostic aspects. 
Historical aspects
As early as 1906, Giovannini described the concurrence of alopecia areata and mycosis fungoides in a 13-year-old girl [ 4 ] . In retrospect, it is safe to assume that this was a case of FMF. In 1957, Pinkus observed mucin deposits in hair follicles and coined the term alopecia mucinosa [ 5 ] . Similar reports were published in the following years. In 1959, Jablonska proposed the term follicular mucinosis, which is predominantly used today [ 6 ] . This diagnosis subsumes two distinct entities: on the one hand, idiopathic follicular mucinosis (although it is subject to debate whether this is a distinct entity); on the other hand, a variant that is associated with cutaneous T-cell lymphoma (mycosis fungoides, Sézary syndrome, lymphomatoid papulosis, adult T-cell leukemia 
Epidemiology
Most studies have shown a male preponderance [ 3, 7, 8 ] , with a male-to-female ratio of 2-5 : 1 [ 7, 9, 10 ] . The majority of patients develop the disease in adulthood; the mean age of onset has been reported to vary from 46 to 59 years [ 3, [7] [8] [9] [10] [11] .
However, FMF can also occur in childhood and is a common variant of juvenile mycosis fungoides, a generally rare disease [ 12, 13 ] . On average, the diagnosis is made 18-48 months after the onset of skin lesions [ 8, 10 ] .
Clinical spectrum
FMF is characterized by a broad clinical spectrum that comprises a variable combination of follicular lesions. A number of studies [ 3, [8] [9] [10] [11] 14 ] have investigated the frequency of the various clinical manifestations summarized in Table 1 . The characteristic manifestations of classic mycosis fungoidespatches, plaques, and tumors -are also the most common clinical fi ndings associated with FMF, albeit with follicular accentuation (Figure 1 a-d) . The plaques are frequently associated with alopecia ( Figure 1 is a typical feature of FMF, occurring in up to 81 % of patients [ 3 ] . Involvement of the eyebrows is highly characteristic and may present an early disease manifestation as well as a useful clue in the differential diagnosis ( Figure 3 a-d) [ 3 ] . Rare clinical fi ndings include follicular hyperkeratosis, referred to as "spikes" (Figure 2 d) , which may also be a sign of early FMF. In their initial description of eight patients, Tomasini et al [ 15 ] reported these lesions to predominantly occur on the trunk and extremities. By contrast, we have observed similar lesions arising on the face as well (Figure 2 d ). Some patients with FMF may also show severe facial involvement in the form of leonine facies [ 16, 17 ] (Figure 2 e), which is a rare manifestation of MF. A retrospective single-center study has shown that patients thus affected frequently exhibit follicular as well as peripheral blood involvement [ 17 ] ; the overall prognosis is poor [ 17 ] . A small number of FMF patients (6 %) may develop erythroderma. Here, too, the follicular component is usually still apparent (Figure 2 f) . While the head and neck region is commonly reported to be the site of predilection for FMF lesions, up to 73 % of patients also exhibit skin lesions on the trunk and the extremities. Recent studies [ 2, 3 ] indicate that FMF can be divided into two subtypes. This is also refl ected in the clinical manifestation (please refer to the section on "prognosis and subclassifi cation").
Similar to classic mycosis fungoides, there is also a unilesional variant of FMF, with 17 cases published to date [18] [19] [20] [21] [22] [23] . Although progression to tumor stage and large-cell transformation may occur, this process appears to be localized, too. Curative radiation therapy is possible [ 20 ] and the prognosis is excellent.
In adults, pruritus is a common symptom [ 3, 7 ] that is often diffi cult to manage. By contrast, there is only mild pruritus in children with FMF [ 24 ] . In children, FMF appears to be a rather common manifestation of juvenile MF, which in turn is a rare disease overall [ 12, 13 ] . Hodak et al reported that 36 % of their juvenile MF patients exhibited follicular involvement [ 12 ] . Unlike adult FMF, however, comedo-like lesions, cysts, and abscesses are largely absent [ 12, 24 ] . Clinical fi ndings primarily include keratosis pilaris-like lesions that predominantly affect the trunk. They may best be classifi ed as an early form of FMF [ 12 ] . In general, the clinical course is milder than in adults, although a more aggressive clinical behavior has been observed in rare cases [ 25 ] .
The vast majority of posttransplant lymphoproliferative disorders typically are EBV-associated B-cell neoplasms [ 26 ] . Among T-cell malignancies, MF is one of the most common lymphomas and shows an above-average occurrence of follicular involvement [ 26 ] . Similar to pediatric lymphomas, the lesions predominantly develop on the trunk. Overall, the prognosis appears to be favorable.
Clinical differential diagnosis
The spectrum of differential diagnoses to be considered may vary greatly, depending on the predominant clinical fi ndings. A summary of the most important differential diagnoses is provided in Table 2 . Making a defi nitive diagnosis often requires clinicopathologic correlation and possibly additional (immuno-) histochemical and molecular diagnostic tests.
Histopathology
Gerami and Guitart [ 7 ] have proposed fi ve distinct characteristic histomorphological patterns of FMF (Table 3 ) .
Considering the results of other studies as well [ 3, 7, 9, 10, 14, 27 ] , almost all biopsies are characterized by a lymphocytic infi ltrate with perifollicular accentuation; up to 36 % of cases also show cysts [ 9 ] (Figure 4 a) . The interfollicular epidermis is frequently spared [ 10 ] . Pautrier's microabscesses are rarely seen [ 10, 11 ] . There may be signifi cant variability in lymphocyte pleomorphism. Besides mild atypia [ 10 ] , fi ndings may also include distinctly pleomorphic lymphocytes and even large-cell transformation; the latter is observed in approximately 15 % of all biopsies [ 3, 9 ] . Occasionally, there is CD30 Table 3 The five characteristic histomorphological patterns of folliculotropic mycosis fungoides; modified after Gerami and Guitart [ 7 ] .
1 "Prototypic" pattern with intact hair follicles, folliculotropism with or without follicular mucinosis 2 Basaloid folliculolymphoid hyperplasia with folliculotropism 3 Granulomatous dermatitis associated with a follicular destruction 4 Eosinophilic folliculitis 5 Follicular cysts with folliculotropism CD2 and CD3 (Figure 5 a) . Antigen loss (for example CD2, CD3, CD4) has been described and may be useful for further diagnostic differentiation. Typically, there is a marked shift in the CD4/CD8 ratio, usually in favor of CD4 (Figure 5 b, c), resulting in a ratio of 6 to 10 : 1 in the vast majority of cases [ 7 ] . Remarkably, however, this shift is not only caused by neoplastic T lymphocytes but also refl ects an increase in the number of Langerhans cells, which also express CD4 [ 7 ] . Isolated cases of CD8-positive FMF have also been reported [ 14 ] . In addition, there may be variable expression of CD30, which is associated with large-cell transformation in some cases.
Molecular diagnostic workup
Today, PCR according to the Biomed-2 protocol is preferably used to analyze T-cell receptor (TCR) gene rearrange-
Immunohistochemistry
Given that the neoplastic cells in FMF are T lymphocytes, it is possible to detect expression of pan-T-cell markers such as Table 4 Literature review of histological patterns of folliculotropic mycosis fungoides. trated in approximately 75-100 % of all biopsies [ 9, 24, [27] [28] [29] [30] .
Histological differential diagnosis
The most important histological differential diagnoses include follicular eczema, pseudolymphomatous folliculitis, and follicular lymphomatoid papulosis [ 31, 32 ] . Moreover, similar histomorphological patterns can be seen in Sézary syndrome and adult T-cell leukemia. Here, the diagnosis must be based on both clinical fi ndings and additional blood tests. Follicular eczema is usually characterized by prominent involvement of the interfollicular epidermis with spongiosis, yet no signifi cant lymphocytic atypia or follicular mucinosis. Pseudolymphomatous folliculitis shows a folliculotropic infi ltrate predominantly consisting of T cells, with admixture of a signifi cant number of S100-positive and CD1a-positive cells as well as B cells [ 7 ] . Differentiation of follicular lymphomatoid papulosis (LyP) from folliculotropic mycosis fungoides associated with CD30 expression requires that both history and clinical presentation be taken into account [ 31 ] ; the former is characterized by a "coming and going" of papules [ 33 ] . However, clinical overlap or concurrence of both disorders is likewise possible. Again, clinicopathologic correlation is crucial, given that both conditions (LyP and FMF) may present with an identical TCR rearrangement pattern [ 34 ] . Some authors have suggested that these two disorders are merely different manifestations of the same disease entity.
Follicular mucinosis
There has been an extensive debate in the literature about the potential signifi cance of follicular mucinosis (mucin deposits in the follicular epithelium). While some authors proposed a distinction between FMF with and without associated follicular mucinosis [ 10 ] , this concept has not prevailed. Although there have also been reports of "idiopathic" follicular mucinosis (iFM), others have suggested that these cases may merely represent unilesional FMF. Cerroni et al. [ 23 ] reported that 68 % of patients with iFM had a solitary lesion, typically (93 %) located in the head and neck region. These patients were younger than individuals with FMF-associated follicular mucinosis (37.5 vs. 52.2 years) [ 23 ] . Remarkably, however, it has been shown that 54.4 % of patients with iFM show monoclonal T-cell rearrangement, compared to 47.4 % of patients with FMF-associated follicular mucinosis [ 34 ] . It is our opinion that iFM cannot be reliably distinguished from unilesional FMF. Indeed, the question arises whether they truly represent two different entities or rather a disease spectrum. However, given that both entities have an excellent prognosis, the precise nomenclature is of secondary importance.
ment. While analysis of the gamma chain is routinely done in many laboratories, analysis of the beta chain may also be useful. Monoclonal TCR rearrangement can be demons-
Prognosis and subclassification
Until recently, it had been assumed that FMF was generally associated with a 5-year survival rate of 66-80 %, thus resembling the prognosis of classic tumor-stage MF [ 1 ] . This assumption was predominantly based on studies from 2000 and 2001 [ 10, 35 ] . By contrast, case reports, small case series [ 12, 26 ] , and our own observations suggest that not all patients with FMF have an unfavorable prognosis. Two recent studies have confi rmed these observations and shown that FMF can be divided into an early/indolent and an advanced/ aggressive variant [ 2, 3 ] . Patients with early FMF had 5-year and 10-year survival rates of 92 % and 72 %, respectively; those with advanced FMF, 55 % and 28 %. In patients with organ involvement at the time of diagnosis, 5-year and 10-year survival rates dropped to 23 % and 2 %, respectively. Individuals with early/indolent FMF typically (100 %) de- veloped lesions on the trunk (Figure 6 a) , whereas the head and neck region was less commonly affected (40 %). Histologically, the infi ltrate was frequently more superfi cial and less dense (Figure 6 b) . On the other hand, the head and neck region was affected in 100 % of patients with advanced/aggressive FMF (Figure 6 c) ; in 20 % of cases, it was the only site affected [ 2 ] . In advanced/aggressive FMF, there was more prominent infi ltration of the plaques as well as a greater number of tumorous nodules. Consequently, the histological picture was characterized by greater density and depth of the perifollicular infi ltrates. Eosinophils and plasma cells were frequently observed (Figure 6 d) , and involvement of the sweat glands (syringotropism) was more common. In addition, pruritus was more severe in advanced FMF compared to early/indolent FMF [ 2 ] . The various characteristics of early/indolent and advanced/aggressive FMF are compared in Table 5 and Figure 6 a-d. Van Santen et al. also described a Table 6 Therapeutic options for folliculotropic mycosis fungoides.
-Topical treatment: topical corticosteroids, (topical bexarotene gel*, topical mechlorethamine, topical immunotherapy, for example resiquimod*) -Phototherapy: narrowband UVB (311 nm), PUVA -Systemic treatment: interferon alpha, bexarotene, methotrexate, gemcitabine, liposomal doxorubicin, brentuximab vedotin**, polychemotherapy, pralatrexate*, alemtuzumab -Radiation therapy (locally or total body irradiation) -Extracorporeal photopheresis -Possibly stem cell transplantation *No approval in Germany; **in particular in case of CD30 expression, currently no approval for this indication in Germany.
third subgroup of FMF, which is associated with extracutaneous involvement [ 3 ] .
Treatment
Similar to classic MF, therapeutic options include topical agents, phototherapy, and various systemic drugs. All of these interventions should be employed in an appropriately stage-adjusted manner (please refer to the S2k guidelines "Cutaneous lymphomas -Update 2016" [ 36 ] ). Overall, FMF is associated with a poorer response to treatment. In the case of topical agents and phototherapy, this may likely be attributed to the depth and location of the infi ltrates. However, systemic treatment presents a particular challenge, too. The reasons for the poor response to systemic agents are unknown. Combination therapy is generally useful. Common combinations include topical corticosteroids and narrowband UVB (311 nm) or PUVA therapy. If the response is inadequate, the addition of oral bexarotene has been shown to be benefi cial [ 37, 38 ] . Other systemic options are interferon alpha or methotrexate (MTX). Patients who do not adequately respond to "classic" therapeutic agents may benefi t from extracorporeal photopheresis [ 39 ] . In general, the indication for aggressive systemic treatment should be carefully evaluated. In this context, mono(chemo)-therapies commonly employed include gemcitabine, liposomal doxorubicin, or alemtuzumab. In case of further disease progression, stem cell transplantation should be discussed as a possible option. Polychemotherapy is frequently associated with only a temporary response. Curative radiation therapy is still the treatment of choice for unilesional FMF. An overview of possible therapeutic options is provided in Table 6 . In a recent study, van Santen et al. evaluated response to treatment with regard to the newly proposed FMF variants [ 40 ] . Here, patients with early/indolent FMF showed a good response to less aggressive therapeutic regimens such as topical corticosteroids or phototherapy (UVA or UVB). These interventions were less effective in patients with advanced/aggressive disease [ 40 ] . In the latter group, local radiation therapy, total body irradiation as well as a combination of PUVA therapy and local radiation therapy proved to be effi cacious [ 40 ] . Overall, the study suggests that not all patients with FMF initially require an aggressive therapeutic approach [ 40 ] .
Conclusion
Knowledge of the histological and clinical spectrum of folliculotropic mycosis fungoides is key to early detection and differential diagnosis. The classifi cation of subtypes (indolent/ 
